BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is engaged as a digital technology that is focused on elevating precision medicine through the use of machine learning. Shares of the medical technology company are rallying 30% through afternoon trading on Tuesday, April 4, 2023. Over the past three months, BullFrog AI has seen average daily volume of 522,700 shares. However, volume of 36.43 million shares or dollar volume of around $231.69 million, has already exchanged hands through afternoon trading.

Shares of BullFrog AI are gaining after the company announced it has entered into a global exclusive licensing agreement with Johns Hopkins University Applied Physics Laboratory (APL) to use the patented artificial intelligence (AI) technology, which powers BullFrog AI’s bfLEAP platform.

The bfLEAP platform helps to analyze drug development data in order to develop potentially life-saving treatments to patients more quickly. APL’s patented technology enables analytical models to digest and interpret large amounts of complex and diverse datasets. Even if the data is incomplete or contains both numerical and categorical data, the technology can still provide meaningful results. Furthermore, the patented tech has also known to be a strong performer than well-established algorithms in benchmarking tests.

Included in APL’s licensed technologies is Prometheus and Seagull. Prometheus is a comprehensive library of APL-developed probabilistic models. One of those models recently beat ten competing algorithms in detecting anomalies in a vast benchmarking study using 12 open-source datasets.

Seagull is a comprehensive library of multivariate time series analyses. This allows researchers the ability to enrich time series data by linking it with open-source data, as well as calculated behavioral features.

“The ability to make predictions with incomplete multimodal data and insufficient scalability of digital analytics are two critical issues for researchers and clinicians today,” said Vin Singh, Founder and CEO of BullFrog AI. “With the help of John Hopkins APL’s patented technology, our bfLEAP™ platform is able to overcome these challenges, enabling precise identification of meaningful data for more agile drug development. We are excited to apply this game-changing technology to both our internal drug development and clinical testing initiatives, as well as in strategic relationships with key partners in biopharma.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post BullFrog AI (NASDAQ: BFRG) Secures Global Exclusive Licensing Agreement with Johns Hopkins to Access Patented Artificial Intelligence Technology appeared first on Spotlight Growth.